The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2011, Pages 1-30

  Nikfar, Shekoufeh ^a   Abdollahi, Mohammad ^b   Salari, Pooneh ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

EID: 84856167141     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3g883     Document Type: Article

References (48)

1. American Diabetes Association. Standards for diabetes care-2008. Diabetes Care 2008; 31: S12-S54.
2. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label uncontrolled extension of three double-blind placebo-controlled trials. Clin Ther 2007; 29(1): 139-53.
3. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 134: 281-303.
4. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-9.
5. Yki-Järvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Molec Med 2005; 5: 287-95.
6. Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care 2007; 30: 1562-6.
7. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805-22.
8. Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (Duration-3): an open-label randomized trial. Lancet 2010; 375: 2234-43.
9. Fehse F, Trautmann M, Holst JJ, et al. exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-7.
10. Nielsen LL, Young AA, Parks DG. Pharmacology of exenatide (synthetic exenatide-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77-88.
11. Gedulin BR, Nikoulina SE, Smith PA, et al. exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-76.
12. Kajbaf F, Mojtahedzadeh M, Abdollahi M. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy 2007; 4(1): 97-106.
13. Larijani B, Afshari M, Astanehi-Asghari F, et al. Effect of short-term carvedilol therapy on salivary and plasma oxidative stress parameters and plasma glucose level in type II diabetes. Therapy 2006, 3: 119-23.
14. Vosough-Ghanbari S, Rahimi R, Kharabaf S, et al. Effects of Satureja khuzestanica on serum glucose, lipids and markers of oxidative stress in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial. Evid Based Complement Alternat Med 2010; 7: 465-70.
15. Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of Iranian medicinal plants useful in diabetes mellitus. Arch Med Sci 2008; 4(3): 285-92.
16. Malihi F, Hosseini-Tabatabaei A, Esmaily H, Khorasani R, Baeeri M, Abdollahi M. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Cent Eur J Biol 2009; 4(3): 369-80.
17. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type 2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother 2005; 59: 302-6.
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
19. Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka A, Brodows RG. Exenatide exhibits dosedependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56(3): 415-24.
20. Iwamoto K, Nasu R, Yamamura A, et al. safety tolerability pharmacokinetics and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009; 56(8): 951-62.
21. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized double-blind placebocontrolled parallel-group study. Clin Ther 2008; 30(8): 1448-60.
22. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-93.
23. Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-100.
24. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083-91.
25. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
26. Apovian CM, Gergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123(5): 468. e9-468. e17.
27. Zinman B, Hoogwerf BJ, Garcia SD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007; 146: 477-85.
28. Poon T, Nelson P, Shen L, et al. exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7(3): 467-77.
29. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a doubleblind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010; 9: 6.
30. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
31. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin. Diabetes Care 2010; 33(7): 1509-15.
32. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-7.
33. Ansari G, Mojtahedzadeh M, Kajbaf F, et al. How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines. Adv Ther 2008; 25(7): 681-702.
34. Mojtahedzadeh M, Rouini MR, Kajbaf F, et al. Advantage of adjunct metformin and insulin therapy in the management of glycemia in critically ill patients. Evidence for nonoccurrence of lactic acidosis and needing to parenteral metformin. Arch Med Sci 2008; 4(2): 174-81.
35. Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Ann Pharmacother 2008; 42: 1541-51.
36. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298(2): 194-206.
37. Fakhoury WK, LeReun C, Wright D. A metaanalysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010; 86: 44-57.
38. Monami M, Marchionni N, Mannucci E. Glucagonlike peptide receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009; 160: 909-17.
39. Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol 2009; 15(25): 3073-85.
40. Hayashi T, Kawashima S, Itoh H, et al. Importance of lipid levels in elderly diabetic individuals: baseline characteristics and 1-year survey of cardiovascular events. Circ J 2008; 72: 218-25.
41. Hadjibabaie M, Gholami K, Khalili H, et al. Comparative efficacy and safety of atorvastatin, simvastatin, and lovastatin in the management of dyslipidemic type 2 diabetic patients. Therapy 2006, 3(6): 759-64.
42. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-47.
43. Yamamoto H, Lee CE, Marcus JN, et al. Glucagonlike peptide-receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52.
44. Barragán JM, Roriguez RE, Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994; 266: E459-E466.
45. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide a in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-35.
46. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasoelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-6.
47. Salari P, Nikfar S, Abdollahi M. No Superiority of exenatide over Insulin in Diabetic Patients in Terms of Weight Reduction or Incidence of Adverse Effects: A Meta-Analysis. Int J Pharmacol 2011; Online First; DOI: 10.3923/ijp.2011.
48. Pinelli NR, Hurren KM. Efficacy and safety of longacting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011; 45: 850-60.